These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26514385)

  • 1. [Towards a vaccine against HIV: antibodies raised by a gp41 peptide neutralize the virus and inhibit pathogenesis].
    Vieillard V; Debré P
    Biol Aujourdhui; 2015; 209(2):161-6. PubMed ID: 26514385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1.
    Gohain N; Tolbert WD; Acharya P; Yu L; Liu T; Zhao P; Orlandi C; Visciano ML; Kamin-Lewis R; Sajadi MM; Martin L; Robinson JE; Kwong PD; DeVico AL; Ray K; Lewis GK; Pazgier M
    J Virol; 2015 Sep; 89(17):8840-54. PubMed ID: 26085162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
    Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral immunity to HIV, SIV, and SHIV.
    Haigwood NL; Zolla-Pazner S
    AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
    [No Abstract]   [Full Text] [Related]  

  • 5. Protection of neonatal macaques against experimental SHIV infection by human neutralizing monoclonal antibodies.
    Ruprecht RM; Hofmann-Lehmann R; Smith-Franklin BA; Rasmussen RA; Liska V; Vlasak J; Xu W; Baba TW; Chenine AL; Cavacini LA; Posner MR; Katinger H; Stiegler G; Bernacky BJ; Rizvi TA; Schmidt R; Hill LR; Keeling ME; Montefiori DC; McClure HM
    Transfus Clin Biol; 2001 Aug; 8(4):350-8. PubMed ID: 11642027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV. The modern era of HIV-1 vaccine development.
    Mascola JR
    Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931
    [No Abstract]   [Full Text] [Related]  

  • 7. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
    Neurath AR; Strick N; Lee ES
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies.
    Laal S; Burda S; Gorny MK; Karwowska S; Buchbinder A; Zolla-Pazner S
    J Virol; 1994 Jun; 68(6):4001-8. PubMed ID: 7514683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterologous neutralizing antibody induction in a simian-human immunodeficiency virus primate model: lack of original antigenic sin.
    Rasmussen RA; Montefiori DC; Robinson HL; McClure HM; Ruprecht RM
    J Infect Dis; 2001 Dec; 184(12):1603-7. PubMed ID: 11740737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges.
    Bomsel M; Tudor D; Drillet AS; Alfsen A; Ganor Y; Roger MG; Mouz N; Amacker M; Chalifour A; Diomede L; Devillier G; Cong Z; Wei Q; Gao H; Qin C; Yang GB; Zurbriggen R; Lopalco L; Fleury S
    Immunity; 2011 Feb; 34(2):269-80. PubMed ID: 21315623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.
    Jacob RA; Moyo T; Schomaker M; Abrahams F; Grau Pujol B; Dorfman JR
    J Virol; 2015 May; 89(10):5264-75. PubMed ID: 25673728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV-1 ENVELOPE. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein.
    Chen J; Kovacs JM; Peng H; Rits-Volloch S; Lu J; Park D; Zablowsky E; Seaman MS; Chen B
    Science; 2015 Jul; 349(6244):191-5. PubMed ID: 26113642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to α4β7.
    Lertjuthaporn S; Cicala C; Van Ryk D; Liu M; Yolitz J; Wei D; Nawaz F; Doyle A; Horowitch B; Park C; Lu S; Lou Y; Wang S; Pan R; Jiang X; Villinger F; Byrareddy SN; Santangelo PJ; Morris L; Wibmer CK; Biris K; Mason RD; Gorman J; Hiatt J; Martinelli E; Roederer M; Fujikawa D; Gorini G; Franchini G; Arakelyan A; Ansari AA; Pattanapanyasat K; Kong XP; Fauci AS; Arthos J
    PLoS Pathog; 2018 Aug; 14(8):e1007278. PubMed ID: 30153309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An HIVgp41 vaccine protects CD4 central memory T cells in SHIV-infected macaques.
    Vieillard V; Dereuddre-Bosquet N; Mangeot-Méderlé I; Le Grand R; Debré P
    Vaccine; 2012 Nov; 30(48):6883-91. PubMed ID: 22989687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.
    Xu W; Hofmann-Lehmann R; McClure HM; Ruprecht RM
    Vaccine; 2002 May; 20(15):1956-60. PubMed ID: 11983253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How antibodies block HIV infection: paths to an AIDS vaccine.
    Putney S
    Trends Biochem Sci; 1992 May; 17(5):191-6. PubMed ID: 1350693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral responses to linear epitopes on the HIV-1 envelope in seropositive volunteers after vaccine therapy with rgp160.
    Loomis LD; Deal CD; Kersey KS; Burke DS; Redfield RR; Birx DL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):13-26. PubMed ID: 7544225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.